Preview

Pediatric pharmacology

Advanced search

Diagnostic Study of the Sensitivity of the Population Screening Method for Cognitive Functions in Primary School Children

https://doi.org/10.15690/pf.v22i5.2963

Abstract

Background. Learning difficulties are a common problem in primary school, affecting up to 30–40% of students. They are often associated with mild cognitive impairments, but existing methods for diagnosing them are time-consuming and not suitable for large-scale surveys. This creates a need for quick and accessible screening tools to identify at-risk children in a timely manner. The aim of the study is to conduct a psychometric validation of the developed screening method for assessing cognitive functions in primary school-aged children by comparing its results with generally accepted psychodiagnostic tools. Methods. A one-time observational prospective study involved 102 children aged 7 to 8 years and 11 months. The study used a developed screening method to assess auditory-verbal memory, verbal-logical thinking, constructive praxis, analytical-synthetic abilities for understanding the plot, and voluntary attention. To assess the construct validity, the Wechsler Intelligence Scale for Children (WISC), the A.R. Luria neuropsychological examination, and the Tuloz – Pieron test were used. The relationship between the indicators was assessed using the Spearman rank correlation coefficient. Results. Statistically significant correlations were established between the indicators of all subtests of the screening methodology and similar indicators of validating instruments. In particular, the results of the “Auditory — speech memory” subtest correlated with the indicators of the “10 words” test and the state of phonemic hearing; the “Kohs Block Design” subtest showed high consistency with the classical version of the Wexler test (P = 0.736, P < 0.0001); “Story pictures” — with the performance of the task “Interpretation of plot pictures” (P = 0.587, P < 0.0001); the effectiveness of the Dot cancellation test is associated with the stability of the Toulouse – Pieron attention (P = 0.556, P < 0.0001). Conclusion. The developed screening method demonstrated sufficient construct validity. This tool can be recommended for screening assessment of cognitive functions in order to identify children of primary school age from the risk group for the development of learning difficulties for their subsequent in-depth diagnostics.

About the Authors

Natalia E. Sergeeva
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Natalia E. Sergeeva

10, Fotievoy Str., building 1, Moscow, 119333


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



George A. Karkashadze
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

George A. Karkashadze, MD, PhD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Tinatin Yu. Gogberashvili
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Tinatin Yu. Gogberashvili, MD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Tatiana A. Konstantinidi
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Tatiana A. Konstantinidi, MD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Safarbegim Kh. Sadilloeva
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Safarbegim H. Sadilloeva, MD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Leyla S. Namazova-Baranova
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical University; Shenzhen MSU-BIT University
Russian Federation

Leyla S. Namazova-Baranova, MD, PhD, Professor, Academician of the RAS

Moscow

Shenzhen


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Elena A. Vishneva
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical University
Russian Federation

Elena A. Vishneva, MD, PhD, Professor

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Elena V. Kaytukova
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical University
Russian Federation

Elena V. Kaytukova, MD, PhD, Associate Professor

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Tatiana A. Salimgareeva
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Tatiana A. Salimgareeva, MD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Natalia S. Sergeenko
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Natalia S. Sergienko, MD, PhD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Yulia V. Nesterova
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Yulia V. Nesterova, MD, PhD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Leonid M. Yatsyk
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Leonid M. Yatsyk, MD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Nadezhda A. Ulkina
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Nadezhda A. Ulkina, MD, PhD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Marina A. Kurakina
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Marina A. Kurakina, MD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Svetlana G. Nikitina
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Svetlana G. Nikitina, MD, PhD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Elena S. Zibrova
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Elena S. Zibrova, MD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



Nikita S. Shilko
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery
Russian Federation

Nikita S. Shilko, MD

Moscow


Disclosure of interest:

George A. Karkashadze — lectures for pharmaceutical companies Opella Healthcare Russia, Materia Medica Holding, Geropharm, Organon, and Sotex. Leyla S. Namazova-Baranova — research grants from pharmaceutical companies Pierre Fabre, Genzyme Europe B.V., AstraZeneca Pharmaceuticals LLC, Gilead / PRA Pharmaceutical Research Associates C.I.S., Bionorica, Teva Branded Pharmaceutical Products R&D, Inc / PPD Development (Smolensk) LLC, Stallergen S.A. / Quintiles G.m.b.H. (Austria). The other authors confirmed that there was no conflict of interest that needed to be reported.



References

1. Bezrukikh MM. Trudnosti obucheniya v nachal’noi shkole: prichiny, diagnostika, kompleksnaya pomoshch’. Moscow: Prosveshchenie; 2009. 256 p. (In Russ).

2. Karkashadze GA, Maslova OI, NamazovaBaranova LS. Current Problems of Diagnosis and Treatment of Mild Cognitive Impairments in Children. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2011;8(5):37–41. (In Russ).

3. Arts E, Orobio de Castro B, Luteijn E, et al. Improving social emotional functioning in adolescents with Developmental Language Disorders: a mini review and recommendations. Front Psychiatry. 2022;13:966008. doi: https://doi.org/10.3389/fpsyt.2022.966008

4. Margari L, Buttiglione M, Craig F, et al. Neuro-psychopathological comorbidities in learning disorders. BMC Neurol. 2013;13:198. doi: https://doi.org/10.1186/1471-2377-13-198

5. Flapper BC, Schoemaker MM. Developmental coordination disorder in children with specific language impairment: comorbidity and impact on quality of life. Res Dev Disabil. 2013;34(2):756–763. doi: https://doi.org/10.1186/1471-2377-13-198

6. Weindrich D, Jennen-Steinmetz C, Laucht M, et al. Epidemiology and prognosis of specific disorders of language and scholastic skills. Eur Child Adolesc Psychiatry. 2000;9(3):186–194. doi: https://doi.org/10.1007/s007870070042

7. Tomblin JB, Records NL, Buckwalter P, et al. Prevalence of specific language impairment in kindergarten children. J SpeechHear Res. 1997;40(6):1245–1260. doi: https://doi.org/10.1044/jslhr.4006.1245

8. Norbury CF, Gooch D, Wray C, et al. The impact of nonverbal ability on prevalence and clinical presentation of language disorder: evidence from a population study. J Child Psychol Psychiatry. 2016;57(11):1247–1257. doi: https://doi.org/10.1111/jcpp.12573

9. Katusic SK, Colligan RC, Barbaresi WJ, et al. Incidence of reading disability in a population-based birth cohort, 1976–1982, Rochester, Minn. Mayo Clin Proc. 2001;76(11):1081–1092. doi: https://doi.org/10.4065/76.11.1081

10. Shaywitz SE, Shaywitz BA, Fletcher JM, Escobar MD. Prevalence of reading disability in boys and girls: results of the Connecticut Longitudinal Study. JAMA. 1990;264(8):998–1002.

11. Jovanović G, Jovanović Z, Banković-Gajić J, et al. The frequency of dyscalculia among primary school children. Psychiatr Danub. 2013;25(2):170–174.

12. Attention-Deficit Hyperactivity Disorder in Adults and Children. Adler LA, Spencer TJ, Wilens TE, eds. Cambridge: Cambridge University Press; 2015. 392 p.

13. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–948. doi: https://doi.org/10.1176/ajp.2007.164.6.942

14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington, DC: American Psychiatric Association; 2013.

15. Karkashadze GA, Gogberashvili TYu, Konstantinidi TA, et al. A Single-Stage Population-Based Study of the Prevalence of Mild Cognitive Impairment in Children of Secondary School Age. Annals of the Russian Academy of Medical Sciences. 2023;78(4):329–347. (In Russ). doi: https://doi.org/10.15690/vramn12460

16. Mikadze YuV, Korsakova NK. Neiropsikhologicheskaya diagnostika i korrektsiya mladshikh shkol’nikov v svyazi s neuspevaemost’yu v shkole. Moscow: Pravlenie obshchestva “Znanie” Rossii, TOO “IntelTekh”; 1994. 176 p. (In Russ).

17. Filimonenko YuI, Timofeev VI. Test Vekslera: diagnostika urovnya razvitiya intellekta (detskii variant): Methodological guide. St. Petersburg: Imaton; 2007. 128 p. (In Russ).

18. Glozman ZhM, Soboleva AE. Neiropsikhologicheskaya diagnostika detei shkol’nogo vozrasta: issledovanie vnimaniya, rabotosposobnosti, vospriyatiya, pamyati, myshleniya i rechi. Moscow: Izdatel’stvo MGU; 2003. 224 p. (In Russ).

19. Yasyukova LA. Optimizatsiya obucheniya i razvitiya detei s MMD: test Tuluz-P’erona: Methodological guide. St. Petersburg: Imaton; 2007. 104 p. (In Russ).

20. Melby-Lervåg M, Lyster SA, Hulme C. Phonological skills and their role in learning to read: a meta-analytic review. Psychol Bull. 2012;138(2):322–352. doi: https://doi.org/10.1037/a0026744

21. Stanovich KE. Matthew effects in reading: some consequences of individual differences in the acquisition of literacy. Read Res Q. 1986;21(4):360–407. doi: https://doi.org/10.1598/RRQ.21.4.1

22. Fuchs LS, Fuchs D, Compton DL, et al. The cognitive correlates of third-grade skill in arithmetic, algorithmic computation, and arithmetic word problems. J Educ Psychol. 2006;98(1):29–43. doi: https://doi.org/10.1037/0022-0663.98.1.29

23. Elleman AM. Examining the impact of inference instruction on the reading comprehension of struggling readers: a metaanalysis. J Educ Psychol. 2017;109(6):761–781. doi: https://doi. org/10.1037/edu0000180

24. Groth-Marnat G, Wright AJ. Handbook of Psychological Assessment. 6th edn. Hoboken, NJ: John Wiley & Sons; 2016. 976 p.

25. Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological Assessment. 5th edn. New York: Oxford University Press; 2012. 1200 p.

26. Syndrome of Nonverbal Learning Disabilities: Neurodevelopmental Manifestations. Rourke BP, ed. New York: Guilford Press; 1995. 376 p.

27. Cain K, Oakhill J. Reading comprehension difficulties: correlates, causes, and consequences. In: Children’s comprehension problems in oral and written language: A cognitive perspective. New York: Guilford Press; 2007. pp. 41–75.

28. Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135–168. doi: https://doi.org/10.1146/annurevpsych-113011-143750.


Review

For citations:


Sergeeva N.E., Karkashadze G.A., Gogberashvili T.Yu., Konstantinidi T.A., Sadilloeva S.Kh., Namazova-Baranova L.S., Vishneva E.A., Kaytukova E.V., Salimgareeva T.A., Sergeenko N.S., Nesterova Yu.V., Yatsyk L.M., Ulkina N.A., Kurakina M.A., Nikitina S.G., Zibrova E.S., Shilko N.S. Diagnostic Study of the Sensitivity of the Population Screening Method for Cognitive Functions in Primary School Children. Pediatric pharmacology. 2025;22(5):580-591. (In Russ.) https://doi.org/10.15690/pf.v22i5.2963

Views: 57


ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)